Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab),
physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks
per cycle) until disease progression or unacceptable toxicity.